The expansion, which includes new space for both offices and a laboratory, allows Exagen to accommodate growing test volume for its gastroenterology products and the transition of the company’s newly acquired rheumatology diagnostic products to Albuquerque.
Exagen CEO Scott Glenn said they are pleased to see the rapid adoption of their gene expression tests for the diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.
In addition to commercial laboratory testing, Exagen has an active Re&D group that will use some of the new space to complete various programs in both rheumatology and gastroenterology.
Exagen is focused on discovering and developing tests for individualized diagnostic information to personalized medicine.
